COVID-19: Gastrointestinal manifestations, liver injury and recommendations
Open Access
- 28 January 2022
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (4) , 1140-1163
Abstract
Coronavirus disease 2019 (COVID-19) has caused a pandemic that affected all countries with nearly 270 million patients and 5 million deaths, as of as of December, 2021. The severe acute respiratory syndrome coronavirus 2 virus targets the receptor, angiotensin-converting enzyme 2, which is frequently found in human intestinal epithelial cells, bile duct epithelial cells, and liver cells, and all gastrointestinal system organs are affected by COVID-19 infection. The aim of this study is to review the gastrointestinal manifestations and liver damage of COVID-19 infection and investigate the severe COVID-19 infection risk in patients that have chronic gastrointestinal disease, along with current treatment guidelines. A literature search was conducted on electronic databases of PubMed, Scopus, and Cochran Library, consisting of COVID-19, liver injury, gastrointestinal system findings, and treatment. Liver and intestinal involvements are the most common manifestations. Diarrhea, anorexia, nausea/vomiting, abdominal pain are the most frequent symptoms seen in intestinal involvement. Mild hepatitis occurs with elevated levels of transaminases. Gastrointestinal involvement is associated with long hospital stay, severity of the disease, and intensive care unit necessity. Treatments and follow-up of patients with inflammatory bowel diseases, cirrhosis, hepatocellular carcinoma, or liver transplant have been negatively affected during the pandemic. Patients with cirrhosis, hepatocellular carcinoma, auto-immune diseases, or liver transplantation may have a greater risk for severe COVID-19. Diagnostic or therapeutic procedures should be restricted with specific conditions. Telemedicine should be used in non-urgent periodic patient follow up. COVID-19 treatment should not be delayed in patients at the risk group. COVID-19 vaccination should be prioritized in this group.Keywords
This publication has 112 references indexed in Scilit:
- The gut–liver axis and the intersection with the microbiomeNature Reviews Gastroenterology & Hepatology, 2018
- Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathyInternational Journal of Medical Sciences, 2018
- Landscape of X chromosome inactivation across human tissuesNature, 2017
- ACE2 and MicrobiotaJournal of Cardiovascular Pharmacology, 2015
- Clinical and Histologic Features of Azithromycin-Induced Liver InjuryClinical Gastroenterology and Hepatology, 2015
- Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell–dependent inflammationJournal of Experimental Medicine, 2014
- ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammationNature, 2012
- Overexpression of 7a, a Protein Specifically Encoded by the Severe Acute Respiratory Syndrome Coronavirus, Induces Apoptosis via a Caspase-Dependent PathwayJournal of Virology, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- The Role of Thymus-Expressed Chemokine and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune SystemThe Journal of Immunology, 2000